Safety and Efficacy of Percutaneous Cryoablation for Thoracic Malignancies

Safety and Efficacy of Percutaneous Cryoablation for Thoracic Malignancies - Percutaneous Cryoablation for Thoracic Malignancies

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014996

Enrollment

200

Registered

2014-10-01

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary lung cancer, metastatic lung cancer, mediastinal tumor, chest wall tumor

Interventions

Cryoablation for thoracic malignancies

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Diagnosed as having thoracic malignancies 2)Medically inoperable 3)performance status 0-2 4)16 - 90 years old 5)projected life expectancy of greater than 6 months 6)consent obtained from the attending physician who treats primary tumor (only for patients with metastatic lung tumor) 7)possible to visit the clinic every 3 months after treatment 8)provision of written informed consent

Exclusion criteria

Exclusion criteria: 1)abnormal coagulability 2)active bleeding 3)active infection 4)untreatable brain tumor 5)general anesthesia 6)impossible to communicate 7)prognosis limiting lesion out of thorax 8)more than 10 tumors 9)judged as inadequate by physician

Design outcomes

Primary

Measure	Time frame
Primary outcomes are treatment-related mortality, morbidity, local control and overall survival.	—

Countries

Japan

Contacts

Public ContactTakashi Ohtsuka

School of Medicine, Keio University Division of General Thoracic Surgery, Department of Surgery

ohtsuka@a3.keio.jp03-5363-3806

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026